PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
41.00%
Positive gross profit growth while CRVO is negative. John Neff would see a clear operational edge over the competitor.
27.93%
EBIT growth below 50% of CRVO's 218.15%. Michael Burry would suspect deeper competitive or cost structure issues.
27.93%
Operating income growth above 1.5x CRVO's 7.28%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
29.77%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
30.61%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
30.61%
Diluted EPS growth at 75-90% of CRVO's 40.00%. Bill Ackman would expect further improvements in net income or share count reduction.
2.13%
Share reduction more than 1.5x CRVO's 71.52%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
2.13%
Diluted share reduction more than 1.5x CRVO's 50.65%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
32.67%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
32.86%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.05%
OCF/share CAGR of 83.05% while CRVO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
75.83%
OCF/share CAGR of 75.83% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
20.41%
3Y OCF/share CAGR of 20.41% while CRVO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
95.17%
10Y net income/share CAGR of 95.17% while CRVO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
79.59%
Net income/share CAGR of 79.59% while CRVO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
2.82%
3Y net income/share CAGR of 2.82% while CRVO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
170.99%
Equity/share CAGR of 170.99% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-42.91%
Negative 5Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-60.55%
Negative 3Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while CRVO invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-18.27%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.43%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-31.86%
Our R&D shrinks while CRVO invests at 59.38%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-15.50%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.